<DOC>
	<DOCNO>NCT02275117</DOCNO>
	<brief_summary>The purpose study assess ALD403 prevention migraine headache chronic migraineurs .</brief_summary>
	<brief_title>A Multicenter Assessment ALD403 Chronic Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Diagnosis migraine ≤ 35 year age history chronic migraine ≥ 1 year During 28 day screen period , must ≥ 15 headache day ≥ 8 day assess migraine day least 5 migraine attack record eDiary Headache eDiary complete least 22 28 day prior randomization Confounding pain syndrome ( e.g . fibromyalgia , chronic low back pain , complex regional pain syndrome ) pain syndrome require regular analgesia Psychiatric condition uncontrolled untreated , include condition control minimum 6 month prior screen . History diagnosis complicate migraine ( ICHDIII beta version , 2013 ) , chronic tensiontype headache , hypnic headache , cluster headache , hemicrania continuum , new daily persistent headache , migraine brainstem aura , sporadic familial hemiplegic migraine Unable differentiate migraine headache Subject receive botulinum toxin migraine medical/cosmetic reason require injection head , face , neck within 4 month prior screen . Have clinically significant concurrent medical condition Receipt monoclonal antibody treatment within 6 month screen ( within outside clinical trial ) Previously dose ALD403 monoclonal antibody target CGRP pathway</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Migraine Disorders</keyword>
	<keyword>ALD403</keyword>
</DOC>